Skip to main content
OICR News / Tag

Turnstone Biologics

Browse news tagged Turnstone Biologics.

Browse all news

Filters

Discover the latest news and insightsDiscover the latest news and insights

Filter by pillar All
Filter by format
More stories

Tagged stories

CommercializationTreatment

Ontario start-up makes major deal to develop cancer-fighting viruses

Partners congratulate Turnstone Biologics Canadian academic institutions and research organizations are congratulating Turnstone Biologics on a new partnership with AbbVie to develop cancer-fighting viruses (also called oncolytic viral immunotherapies). Turnstone was founded in Ottawa based…
Article
Collaboration

OICR 2016/17 Annual Report

We are pleased to share the Ontario Institute for Cancer Research (OICR) Annual Report for 2016/17. We are living in an era of unprecedented innovation in cancer research. Recent advances have helped us to better…
Article
TechnologyTreatment

Clinical trial opens for promising combination therapy

The first patient has been treated in what has been named the Sandpiper Trial. The Phase I/II clinical trial will evaluate a therapy that combines a novel oncolytic viral immunotherapy agent called MG1-MAGEA3 with pembrolizumab,…
Article
Newsletter signup

Cancer solved together — in your inbox

The latest findings, funding, and partnerships from Ontario’s cancer research institute. Briefings and deeper dives.

Subscribe
Commercialization

FACIT start-up Turnstone Biologics closes USD $41M financing

OrbiMed, Versant-led round continues commercialization success for Turnstone's cancer therapies TORONTO, Nov. 2, 2016 /CNW/ - Turnstone Biologics Inc. ("Turnstone"), an Ontario-based developer of novel oncolytic viral immunotherapies, announced the closing of a USD $41.4…
Article
Commercialization

From our Annual Report: Investing in the cure and the economy

Ontario has some of the finest cancer researchers in the world who are developing new cancer therapies, diagnostic tools and other anti-cancer technologies. When these novel products make their way into clinical use they improve…
Article